FDA: 3rd hospital secures compassionate special permit to use Ivermectin vs COVID-19 | Inquirer News

FDA: 3rd hospital secures compassionate special permit to use Ivermectin vs COVID-19

/ 01:08 PM April 22, 2021

MANILA, Philippines — Another hospital has been granted a compassionate special permit (CSP) for Ivermectin use against COVID-19, Food and Drug Administration (FDA) Director-General Eric Domingo said Thursday.

Domingo announced this during the hearing of the House committee of good government and public accountability. So far, this is the third hospital in the country to secure a CSP for Uvermectin use against the new coronavirus disease.

However, similar to the first two CSP approvals, Domingo did not disclose the name of the hospital.

ADVERTISEMENT

“Sa ngayon po mayroon pa pong na-approve na isang hospital kahapon,” Domingo said.

FEATURED STORIES

“May pending pa po na isa daw na nag-apply din kahapon na may kulang lang na papel na isu-submit,” he added.

A doctor or a hospital can apply for a CSP when the medicine they want to use is not available or approved here, but registered overseas, Domingo earlier explained.

The FDA, however, stressed that a CSP for any medicine is neither registration of nor a permit to market a drug.

KGA
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: Coronavirus, COVID-19, FDA, Health, hospital, Ivermectin, pandemic, SARS-CoV-2, Virus

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.